Payment overview · 2025
General Payments
$124.93
1 reported records · 1 companies
Healthcare provider profile · identity verified
Isaac Guerrero
Allopathic & Osteopathic Physicians|Family Medicine · CORPUS CHRISTI, TX · NPI 1427443043
Verified facts
What the public records show
CMS Open Payments records show Isaac Guerrero received $124.93 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.93 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.93 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 640 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 485 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 104 |
| Losartan Potassium | Losartan Potassium | 411 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 333 | 104 |
| Lisinopril | Lisinopril | 325 | 98 |
| Metformin Hcl | Metformin Hcl | 209 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 58 |
| Gabapentin | Gabapentin | 169 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 69 |
| Sertraline Hcl | Sertraline Hcl | 157 | 39 |
| Trazodone Hcl | Trazodone Hcl | 156 | 42 |
| Famotidine | Famotidine | 150 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 40 |
| Jardiance | Empagliflozin | 139 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 21 |
| Tramadol Hcl | Tramadol Hcl | 135 | 43 |
| Furosemide | Furosemide | 130 | 42 |
| Donepezil Hcl | Donepezil Hcl | 120 | 25 |
| Simvastatin | Simvastatin | 120 | 34 |
| Eliquis | Apixaban | 115 | 27 |
| Omeprazole | Omeprazole | 112 | 37 |
| Ozempic | Semaglutide | 102 | 26 |
| Metformin Hcl Er | Metformin Hcl | 98 | 30 |
| Atenolol | Atenolol | 93 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 25 |
| Alendronate Sodium | Alendronate Sodium | 79 | 28 |
| Alprazolam | Alprazolam | 79 | 22 |
| Allopurinol | Allopurinol | 78 | 22 |
| Lorazepam | Lorazepam | 78 | 13 |
| Potassium Chloride | Potassium Chloride | 77 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 28 |
| Trulicity | Dulaglutide | 71 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 37 |
| Montelukast Sodium | Montelukast Sodium | 70 | 21 |
| Spironolactone | Spironolactone | 70 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 21 |
| Pregabalin | Pregabalin | 68 | 22 |
| Januvia | Sitagliptin Phosphate | 65 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 43 |
| Clonazepam | Clonazepam | 63 | 12 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 18 |
| Memantine Hcl | Memantine Hcl | 60 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 42 |
| Glimepiride | Glimepiride | 58 | 18 |
| Mirtazapine | Mirtazapine | 56 | 16 |
| Azelastine Hcl | Azelastine Hcl | 53 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 15 |
| Azithromycin | Azithromycin | 50 | 44 |
| Meloxicam | Meloxicam | 50 | 22 |
| Ramipril | Ramipril | 50 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | 19 |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 18 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 13 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Finasteride | Finasteride | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 12 |
| Latanoprost | Latanoprost | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 26 |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 22 |
| Valsartan | Valsartan | 29 | 12 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 16 |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 16 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Ciclopirox | Ciclopirox | 21 | 12 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Estradiol | Estradiol | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.93 · 1 records | ABBVIE INC. | UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error